Pharmacokinetics and Pharmacodynamics Practice Questions

Q: What is the anti-inflammatory dose of aspirin?

3 - 6 g/d. ***3 - 6 g/d*** - The anti-inflammatory effect of aspirin is typically achieved at higher doses, ranging from **3 to 6 grams per day**, often divided into multiple doses. - This dosage range is necessary to significantly inhibit prostaglandin synthesis, which mediates inflammation and pain. *500 mg/d* - This dose is generally considered to be in the **analgesic and antipyretic range**, effectively reducing pain and fever. - It is often insufficient to achieve a full anti-inflammatory effect, as it does not fully saturate the prostaglandin synthesis pathway. *1 - 2 g/d* - While higher than common analgesic doses, **1-2 g/d of aspirin** may have *some* anti-inflammatory effects but is typically considered a moderate dose. - It might not be sufficient for treating significant inflammatory conditions, falling short of the fully recognized anti-inflammatory dose. *6 - 12 g/d* - Doses within this range are generally considered to be in the **toxic or potentially toxic range** for aspirin. - This high dosage can lead to severe side effects such as **salicylism**, including tinnitus, nausea, vomiting, metabolic acidosis, and even coma, and is not a standard therapeutic anti-inflammatory dose.

Q: Which of the following drug substrate combinations is incorrectly matched?

CYP 2C8/9 - mifepristone. ***CYP 2C8/9 - mifepristone*** - **Mifepristone** is primarily metabolized by **CYP 3A4**, not CYP 2C8/9. - CYP 2C8/9 metabolizes drugs like **warfarin**, rosiglitazone, and tolbutamide. *CYP 3A4/5 - simvastatin* - **Simvastatin** is a known substrate for **CYP 3A4/5**, and its metabolism can be significantly affected by CYP 3A4/5 inhibitors or inducers. - This interaction is clinically important for **drug-drug interactions** concerning statin therapy. *CYP 2D6 - SSRI* - Many **Selective Serotonin Reuptake Inhibitors (SSRIs)**, such as fluoxetine, paroxetine, and venlafaxine, are metabolized by **CYP 2D6**. - This makes CYP 2D6 a crucial enzyme in determining **SSRI efficacy** and **side effect profiles**. *CYP 2C19 - omeprazole* - **Omeprazole**, a proton pump inhibitor, is primarily metabolized by **CYP 2C19** and also by CYP 3A4. - Genetic polymorphisms in **CYP 2C19** can significantly affect omeprazole's metabolism and clinical efficacy.

Q: Most common enzyme for drug metabolism and detoxification reactions?

CYP3A4. ***CYP3A4*** - **CYP3A4** is the most abundant and versatile **cytochrome P450 enzyme** in the human liver and intestine, responsible for metabolizing approximately **50% of all clinically used drugs**. - Its broad substrate specificity and high expression levels make it a critical player in **drug detoxification** and metabolism. *CYP1A2* - While important, **CYP1A2** is primarily involved in the metabolism of only about **10% of therapeutic drugs** and specific endogenous compounds. - It plays a significant role in the metabolism of **caffeine** and some **polycyclic aromatic hydrocarbons**, but its overall contribution to drug metabolism is less than that of CYP3A4. *CYP2A6* - **CYP2A6** is a minor **cytochrome P450 enzyme** that metabolizes a limited number of drugs and xenobiotics. - Its primary role is in the metabolism of **nicotine** and certain **tobacco-specific nitrosamines**, making it less globally significant for general drug detoxification compared to CYP3A4. *CYP2B6* - **CYP2B6** metabolizes a relatively small fraction of drugs, around **3% to 5%** of those currently in clinical use. - While it is important for the metabolism of some **antiretrovirals** and **antidepressants**, its contribution to overall drug metabolism and detoxification is considerably less extensive than that of CYP3A4.

Q: Glucuronidation takes place in?

Liver. ***Liver*** - The **liver** is the primary organ responsible for **glucuronidation**, a crucial phase II detoxification pathway [1]. - This process conjugates **glucuronic acid** with various endogenous and exogenous substances, making them more water-soluble for excretion [1]. *RBC* - **Red blood cells (RBCs)** primarily function in **oxygen transport** and lack the extensive metabolic machinery for glucuronidation. - While they possess some enzymatic activities, detoxification pathways like glucuronidation are not a significant function. *Pancreas* - The **pancreas** is mainly involved in producing **digestive enzymes** and **hormones** (insulin, glucagon) for blood glucose regulation. - It does not play a direct role in drug or toxin metabolism through processes like glucuronidation. *Thyroid* - The **thyroid gland** is responsible for producing **thyroid hormones** that regulate metabolism. - Its metabolic activity is distinct from the detoxification functions performed by the liver, and it does not perform glucuronidation.

Q: A patient given digoxin started having side effects like nausea and vomiting. The serum concentration of digoxin was 4 ng/mL. The plasma therapeutic range is 1-2 ng/mL. If the half-life of digoxin is 40 hours, how long should one wait before resuming the treatment?

80 hours. ***80 hours (2 half-lives)***- Current digoxin level is **4 ng/mL**, which is **twice the upper therapeutic limit** (2 ng/mL), causing toxicity with nausea and vomiting [1]- After **1 half-life (40 hours)**: concentration reduces to 2 ng/mL (upper therapeutic limit) [2]- After **2 half-lives (80 hours)**: concentration reduces to 1 ng/mL (mid-therapeutic range) [2]- **Clinical rationale**: While 2 ng/mL is technically within range, waiting for 2 half-lives ensures the level is comfortably in the **middle of the therapeutic window** (1 ng/mL), providing a **safer margin** before resuming treatment in a patient who just experienced toxicity- This conservative approach minimizes risk of recurrent toxicity, especially important given the patient's recent symptoms at 4 ng/mL*1 half-life (40 hours)*- After 1 half-life, digoxin level would be 2 ng/mL, which is at the **upper limit** of the therapeutic range- While technically within the therapeutic range, this leaves **minimal safety margin** in a patient who just experienced toxicity- Starting treatment immediately at this level carries higher risk of recurrent side effects*120 hours (3 half-lives)*- After 3 half-lives, the concentration would be **0.5 ng/mL**, which is **below the therapeutic range** (1-2 ng/mL)- This is overly conservative and would **unnecessarily delay** resumption of essential cardiac medication- Could lead to inadequate control of the underlying condition (heart failure or atrial fibrillation)*140-180 hours (3.5-4.5 half-lives)*- This would reduce digoxin to **0.25-0.35 ng/mL**, well below therapeutic levels- This **excessive delay** is not clinically justified and could worsen the patient's cardiac condition- No standard protocol recommends waiting this long before resuming digoxin therapy

Q: Pegloticase reduces serum uric acid levels by which mechanism?

Converts uric acid to allantoin. ***Converts uric acid to allantoin*** - Pegloticase is a **recombinant uricase enzyme** that catalyzes the oxidation of uric acid to **allantoin**. - Allantoin is a **water-soluble** substance that is easily excreted by the kidneys, thereby lowering serum uric acid levels. *Inhibits xanthine oxidase* - This is the mechanism of action for drugs like allopurinol and febuxostat, which prevent the formation of uric acid. - Pegloticase works downstream of uric acid formation, by enhancing its degradation. *Inhibits uric acid reabsorption in the kidneys* - This is the mechanism of action for **uricosuric agents** such as probenecid and lesinurad. - These drugs increase the excretion of uric acid by acting on transporters in the renal tubules, but this is not how pegloticase works. *Increases renal excretion of uric acid* - While pegloticase ultimately leads to increased renal excretion of allantoin, its primary mechanism is the **conversion of uric acid to allantoin**, not direct action on renal tubules to excrete uric acid. - Uricosuric agents directly increase renal excretion of uric acid.

Q: Which of the following statements is true about noncompetitive enzyme inhibitors?

Km remains same, Vmax decreases. ***Km remains same, Vmax decreases*** - **Noncompetitive inhibitors** bind to an allosteric site on the enzyme, altering its conformation and **reducing its catalytic efficiency** without affecting substrate binding affinity. - This results in a decreased **Vmax** (maximum reaction rate) because the enzyme's ability to process substrate is impaired, while the **Km** (substrate concentration at half Vmax) remains unchanged as the substrate can still bind efficiently to the active site. *Noncompetitive inhibitors increase Km and decrease Vmax* - This statement is incorrect because noncompetitive inhibitors primarily affect the enzyme's **catalytic activity** (Vmax) rather than its affinity for the substrate (Km). - An increase in **Km** would imply a decrease in the enzyme's affinity for the substrate, which is characteristic of **competitive inhibition**, not noncompetitive inhibition. *Km decreases, Vmax increases* - This statement describes an effect not typically seen with noncompetitive inhibition; a decreased **Km** would imply increased substrate affinity, and an increased **Vmax** would suggest enhanced catalytic efficiency. - Noncompetitive inhibitors are known to **reduce** the maximum reaction rate, not increase it. *Km increases, Vmax increases* - This scenario, where both **Km** and **Vmax** increase, is not characteristic of any standard type of enzyme inhibition. - An increase in **Vmax** implies an enhancement in enzyme activity, which is contrary to the action of an inhibitor.

Q: Which fluoroquinolone has the maximum bioavailability?

Levofloxacin. ***Levofloxacin*** - **Levofloxacin** exhibits high oral bioavailability, approximately 99%, meaning nearly all of the administered dose reaches systemic circulation [1]. - This high bioavailability allows for seamless transition from intravenous to oral administration without significant changes in drug exposure [1]. *Moxifloxacin* - **Moxifloxacin** has a high bioavailability of approximately 90%, which is slightly lower than levofloxacin's almost complete absorption [1]. - While excellent, it is not the absolute highest among fluoroquinolones. *Gatifloxacin* - **Gatifloxacin** has good oral bioavailability, around 96%, but it is still generally considered slightly less than that of levofloxacin [1]. - This difference, though small, makes levofloxacin the one with the highest overall bioavailability. *Ciprofloxacin* - **Ciprofloxacin** has the lowest oral bioavailability among the listed fluoroquinolones, ranging from 70% to 80% [1]. - Its absorption can be significantly impaired by co-administration with multivalent cations, leading to reduced systemic concentrations.

Q: At pKa = pH, what is the relationship between the ionic and non-ionic forms of a drug?

Conc. of drug is 50% ionic and 50% non-ionic. ***Conc. of drug is 50% ionic and 50% non-ionic*** - At **pKa = pH**, the concentrations of the **ionized** and **unionized** forms of a drug are equal as per the **Henderson-Hasselbalch equation**. - This means that exactly **half** of the drug molecules are in their charged (ionic) state, and the other half are in their uncharged (non-ionic) state. *Absorption of drug is 50% ionic and 50% non-ionic* - The amount of drug that is absorbed is dependent on the **non-ionic concentration** available at the absorption site, but this option incorrectly states that the *absorption itself* is 50% ionic. - Absorption primarily occurs for the **non-ionic, lipophilic form** as it can more readily cross cell membranes. *Conc. of drug is 75% ionic and 25% non-ionic* - This ratio would occur when the **pH** is either 0.5 units above the pKa for a weak acid or 0.5 units below the pKa for a weak base. - For example, if **pH = pKa + 0.5** (for a weak acid), approximately 75% would be ionic. *Conc. of drug is 25% ionic and 75% non-ionic* - This ratio would occur when the **pH** is either 0.5 units below the pKa for a weak acid or 0.5 units above the pKa for a weak base. - For example, if **pH = pKa - 0.5** (for a weak acid), approximately 25% would be ionic.

Question 1

What is the anti-inflammatory dose of aspirin?

Accepted Answer

3 - 6 g/d

Answer

500 mg/d

Answer

1 - 2 g/d

Answer

6 - 12 g/d

Question 2

Which of the following drug substrate combinations is incorrectly matched?

Accepted Answer

CYP 2C8/9 - mifepristone

Answer

CYP 3A4/5 - simvastatin

Answer

CYP 2D6 - SSRI

Answer

CYP 2C19 - omeprazole

Question 3

Most common enzyme for drug metabolism and detoxification reactions?

Accepted Answer

CYP3A4

Answer

CYP1A2

Answer

CYP2A6

Answer

CYP2B6

Question 4

Glucuronidation takes place in?

Accepted Answer

Liver

Answer

RBC

Answer

Pancreas

Answer

Thyroid

Question 5

A patient given digoxin started having side effects like nausea and vomiting. The serum concentration of digoxin was 4 ng/mL. The plasma therapeutic range is 1-2 ng/mL. If the half-life of digoxin is 40 hours, how long should one wait before resuming the treatment?

Accepted Answer

80 hours

Answer

120 hours

Answer

140-180 hours

Answer

1 half-life (40 hours)

Question 6

Pegloticase reduces serum uric acid levels by which mechanism?

Accepted Answer

Converts uric acid to allantoin

Answer

Inhibits xanthine oxidase

Answer

Inhibits uric acid reabsorption in the kidneys

Answer

Increases renal excretion of uric acid

Question 7

Which of the following statements is true about noncompetitive enzyme inhibitors?

Accepted Answer

Km remains same, Vmax decreases

Answer

Noncompetitive inhibitors increase Km and decrease Vmax

Answer

Km decreases, Vmax increases

Answer

Km increases, Vmax increases

Question 8

Imipenem, a newer antibiotic with a broad antibacterial spectrum, is co-administered with cilastatin. What is the primary reason for this combination?

Accepted Answer

Cilastatin prevents the degradation of imipenem by inhibiting an enzyme in the kidneys.

Answer

Cilastatin enhances the gastrointestinal absorption of imipenem.

Answer

Cilastatin inhibits the beta-lactamase enzyme that degrades imipenem.

Answer

The combination of antibiotics is synergistic against Pseudomonas species.

Question 9

Which fluoroquinolone has the maximum bioavailability?

Accepted Answer

Levofloxacin

Answer

Gatifloxacin

Answer

Ciprofloxacin

Answer

Moxifloxacin

Question 10

At pKa = pH, what is the relationship between the ionic and non-ionic forms of a drug?

Accepted Answer

Conc. of drug is 50% ionic and 50% non-ionic

Answer

Absorption of drug is 50% ionic and 50% non-ionic

Answer

Conc. of drug is 25% ionic and 75% non-ionic

Answer

Conc. of drug is 75% ionic and 25% non-ionic

Pharmacokinetics and Pharmacodynamics — MCQs

Pharmacokinetics and Pharmacodynamics — MCQs

On this page

Practice by Chapter

Want unlimited practice?